A new type of bone marrow transplant can cure sickle cell disease with only half of the donor's cell proteins matching, ...

CircNova, a Michigan-based biotech startup, has completed a $3.3 million seed round to advance its technology, which uses ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was downgraded by research analysts at Mizuho from an “outperform” ...

Traditional therapies, such as cognitive-behavioral therapy (CBT), psychodynamic therapy, and supportive counseling, have ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Unpacking your problems for an hour each week with a professional is being talked about for all the wrong reasons ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

A new study identifies GPR107 as a key protein protecting against diabetic nephropathy (DN), a major cause of kidney failure.